Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find enclosed herewith the transcript of "Q4 FY2024 Earnings Conference Call" hosted by the Company on 29th May, 2024.03-06-2024
03-06-2024
Alkem Shares Drop To Nearly Three-Week Low As Q4 Profit Misses Estimates
The stock fell as much as 6.99% during the day to Rs 4,894.60 apiece on the NSE.30-05-2024
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find enclosed the details of investor meet scheduled on to be held on 04th and 05th June, 2024.29-05-2024
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the 'Q4FY24 and FY 24 Earnings Conference Call' is available on the website of the Company at https://www.alkemlabs.com/investors/earnings-call.29-05-2024
Alkem Laboratories Results Earnings Call for Q4FY24
Conference Call with Alkem Laboratories Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.29-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Alkem Laboratories Ltd.
Pharmaceuticals company Alkem Laboratories announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Total Revenue from Operations were Rs 29,358 million, YoY growth of 1.1%. India sales were Rs 19,724 million, YoY de-growth of 1.9%. International sales were Rs 9,096 million, YoY growth of 6.1%. Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 4,020 million, resulting in EBITDA margin of 13.7% vs. 12.2% in Q4FY23. EBITDA increased by 13.8% YoY. R&D; expenses for the quarter was Rs 1,757 million, or 6.0% of total revenue from operations compared to Rs 1,472 million in Q4FY23 at 5.1% of total revenue from operations Profit before tax (PBT) before exceptional item was Rs 3,799 million, a growth of 20.7% compared to Rs 3,146 million in Q4FY23. Net Profit (after Minority Interest) was Rs 2,936 million, YoY growth of 313.6%. PAT for Q4FY23 was impacted on account of derecognition of deferred tax of Rs 1,197 million. Adjusted for the above item, PAT growth for Q4FY24 would have been 54%. As per IQVIA data, for Q4FY24, the company registered a growth of 1.4% YoY vs. the Indian Pharmaceutical Market (IPM) which grew by 5.7% FY24 Financial Highlights: Total Revenue from Operations was Rs 1,26,676 million, YoY growth of 9.2%. India sales were Rs 84,337 million, YoY growth of 5.4%. International sales were Rs 40,024 million, YoY growth of 16.4%. Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 22,455 million, resulting in EBITDA margin of 17.7% vs. 13.9% in FY23. EBITDA increased by 39.5% YoY. R&D; expenses for FY24 was Rs 5,229 million, or 4.1% of total revenue from operations compared to Rs 5,394 million in FY23 at 4.7% of total revenue from operations Profit before tax (PBT) before exceptional item was Rs 21,446 million, a growth of 52.3% compared to Rs 14,078 million in FY23. Net Profit (after Minority Interest) was Rs 17,958 million, YoY growth of 82.5%. PAT for FY23 was impacted on account of derecognition of deferred tax of Rs 1,197 million. Adjusted for the above item, PAT growth for FY24 would have been 62.7%. As per IQVIA data, for FY24, the company registered a growth of 6.2% YoY, vs. the Indian Pharmaceutical Market (IPM) which grew by 7.6% We are pleased to share that the international business has crossed revenue of Rs 40 billion in FY24. Commenting on the FY24 results, Vikas Gupta, CEO, Alkem said "Our focus has been to improve EBIDTA margin during the year, on the back of benefits through various cost -control initiatives being implemented along with favourable API prices. Continuing our trend of improved performance, Q4FY24 builds on the momentum gained from previous quarters with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US. Lower Opex across our manufacturing facilities and R&D; also aided EBDITA margin. Our Biosimilars and international business has delivered strong growth across geographies. Our anti-diabetic portfolio continues to outperform the market. We are committed to carrying forward the momentum of better operational performance, building on our recent success." Result PDF29-05-2024
Alkem Laboratories Ltd - 539523 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed herewith the Annual Secretarial Compliance Report for the period ended 31st March, 2024 issued by Practising Company Secretary.29-05-2024
Alkem Laboratories Ltd - 539523 - Closure of Trading Window
The Financial Results of the Company for the quarter and year ended 31st March 24 having been communicated to the Stock Exchanges today 29th May, 2024 , the trading window shall open on 3rd June, 202429-05-2024
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pl. find enclosed press release and analyst presentation on Q4FY24 and FY 24 earnings and business updates of the Company29-05-2024
Alkem Laboratories Ltd - 539523 - Corporate Action - Fixes Record Date For Payment Of Dividend And Cut Off Date For AGM
The BOD at its meeting held today has fixred 10.8.24 as the record date for payment of final dividend and 23.08.24 as cut off date for purpose of AGM29-05-2024